Cargando…

Clinical and cognitive characteristics of preclinical Alzheimer's disease in the Japanese Alzheimer's Disease Neuroimaging Initiative cohort

INTRODUCTION: The objective of this study was to determine the frequency and clinical and cognitive characteristics of preclinical Alzheimer's disease (AD) in a Japanese population to effectively design and conduct future preventive trials on preclinical AD. METHODS: Three-year longitudinal dat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ihara, Ryoko, Iwata, Atsushi, Suzuki, Kazushi, Ikeuchi, Takeshi, Kuwano, Ryozo, Iwatsubo, Takeshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2018
Materias:	Featured Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6258138/ https://www.ncbi.nlm.nih.gov/pubmed/30511010 http://dx.doi.org/10.1016/j.trci.2018.10.004

Ejemplares similares

Effects of sex, educational background, and chronic kidney disease grading on longitudinal cognitive and functional decline in patients in the Japanese Alzheimer's Disease Neuroimaging Initiative study
por: Iwata, Atsushi, et al.
Publicado: (2018)

Identification of prognostic factors to predict cognitive decline of patients with early Alzheimer's disease in the Japanese Alzheimer's Disease Neuroimaging Initiative study
por: Yagi, Takuya, et al.
Publicado: (2019)

Effect of apolipoprotein E ε4 allele on the progression of cognitive decline in the early stage of Alzheimer's disease
por: Suzuki, Kazushi, et al.
Publicado: (2020)

Visualizing modules of coordinated structural brain atrophy during the course of conversion to Alzheimer's disease by applying methodology from gene co-expression analysis
por: Sato, Kenichiro, et al.
Publicado: (2019)

The past, present, and future of disease-modifying therapies for Alzheimer’s disease
por: SUZUKI, Kazushi, et al.
Publicado: (2017)

Efficacy and Cost-effectiveness of Promotion Methods to Recruit Participants to an Online Screening Registry for Alzheimer Disease Prevention Trials: Observational Study
por: Sato, Kenichiro, et al.
Publicado: (2021)

Different AT(N) profiles and clinical progression classified by two different N markers using total tau and neurofilament light chain in cerebrospinal fluid
por: Kasuga, Kensaku, et al.
Publicado: (2022)

Sample Size Estimation for Alzheimer’s Disease Trials from Japanese ADNI Serial Magnetic Resonance Imaging
por: Fujishima, Motonobu, et al.
Publicado: (2017)

The prevalence and biomarkers’ characteristic of rapidly progressive Alzheimer's disease from the Alzheimer's Disease Neuroimaging Initiative database
por: Ba, Maowen, et al.
Publicado: (2017)

Systematic review and meta-analysis of Japanese familial Alzheimer's disease and FTDP-17
por: Kasuga, Kensaku, et al.
Publicado: (2015)

Attempt to Predict A/T/N-Based Alzheimer’s Disease Cerebrospinal Fluid Biomarkers Using a Peripheral Blood DNA Methylation Clock
por: Sato, Kenichiro, et al.
Publicado: (2020)

Effects of traumatic brain injury and posttraumatic stress disorder on development of Alzheimer's disease in Vietnam Veterans using the Alzheimer's Disease Neuroimaging Initiative: Preliminary report
por: Weiner, Michael W., et al.
Publicado: (2017)

Preclinical Alzheimer's disease and longitudinal driving decline
por: Roe, Catherine M., et al.
Publicado: (2016)

Enhancer variants associated with Alzheimer’s disease affect gene expression via chromatin looping
por: Kikuchi, Masataka, et al.
Publicado: (2019)

Cross-validation of optimized composites for preclinical Alzheimer's disease
por: Donohue, Michael C., et al.
Publicado: (2016)

Reduced plasma desmosterol-to-cholesterol ratio and longitudinal cognitive decline in Alzheimer's disease
por: Sato, Yoshiaki, et al.
Publicado: (2015)

Altered γ-secretase activity in mild cognitive impairment and Alzheimer's disease
por: Kakuda, Nobuto, et al.
Publicado: (2012)

African Americans are less likely to enroll in preclinical Alzheimer's disease clinical trials
por: Zhou, Yan, et al.
Publicado: (2016)

Baseline demographic, clinical, and cognitive characteristics of the Alzheimer's Prevention Initiative (API) Autosomal‐Dominant Alzheimer's Disease Colombia Trial
por: Rios‐Romenets, Silvia, et al.
Publicado: (2020)

Disruption of a RAC1-centred network is associated with Alzheimer’s disease pathology and causes age-dependent neurodegeneration
por: Kikuchi, Masataka, et al.
Publicado: (2020)

Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer’s disease
por: Wang, Xiaoqi, et al.
Publicado: (2020)

Molecular Pathogenesis and Disease-modifying Therapies of Alzheimer’s Disease and Related Disorders
por: Iwatsubo, Takeshi
Publicado: (2022)

Optimizing the preclinical Alzheimer's cognitive composite with semantic processing: The PACC5
por: Papp, Kathryn V., et al.
Publicado: (2017)

Latent class analysis identifies functional decline with Amsterdam IADL in preclinical Alzheimer's disease
por: Villeneuve, Sarah-Christine, et al.
Publicado: (2019)

The Worldwide Alzheimer's Disease Neuroimaging Initiative: ADNI‐3 updates and global perspectives
por: Weber, Christopher J., et al.
Publicado: (2021)

Serum microRNA miR-501-3p as a potential biomarker related to the progression of Alzheimer’s disease
por: Hara, Norikazu, et al.
Publicado: (2017)

Analyses of natural courses of Japanese patients with Alzheimer's disease using placebo data from placebo-controlled, randomized clinical trials: Japanese Study on the Estimation of Clinical course of Alzheimer's disease
por: Watanabe, Mitsunori, et al.
Publicado: (2019)

Cerebrospinal fluid neurogranin/β-site APP-cleaving enzyme 1 predicts cognitive decline in preclinical Alzheimer's disease
por: Kirsebom, Bjørn-Eivind, et al.
Publicado: (2018)

The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer's disease, including a placebo-treated noncarrier cohort
por: Tariot, Pierre N., et al.
Publicado: (2018)

The effect of diagnostic criteria on outcome measures in preclinical and prodromal Alzheimer's disease: Implications for trial design
por: Bertens, Daniela, et al.
Publicado: (2017)

Targeting butyrylcholinesterase for preclinical single photon emission computed tomography (SPECT) imaging of Alzheimer's disease
por: DeBay, Drew R., et al.
Publicado: (2017)

Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification
por: Izzo, Nicholas J., et al.
Publicado: (2021)

Q & A: The Alzheimer's disease neuroimaging initiative
por: Aisen, Paul S
Publicado: (2011)

State‐of‐the‐art of lumbar puncture and its place in the journey of patients with Alzheimer's disease
por: Hampel, Harald, et al.
Publicado: (2021)

Contribution of Alzheimer's biomarkers and risk factors to cognitive impairment and decline across the Alzheimer's disease continuum
por: Tosun, Duygu, et al.
Publicado: (2021)

Alzheimer's disease assessment scale-cognitive 11-item progression model in mild-to-moderate Alzheimer's disease trials of bapineuzumab
por: Samtani, Mahesh N., et al.
Publicado: (2015)

Predicting amyloid risk by machine learning algorithms based on the A4 screen data: Application to the Japanese Trial‐Ready Cohort study
por: Sato, Kenichiro, et al.
Publicado: (2021)

Clusters of male and female Alzheimer’s disease patients in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database
por: Gamberger, Dragan, et al.
Publicado: (2016)

Biomarkers and phenotypic expression in Alzheimer’s disease: exploring the contribution of frailty in the Alzheimer’s Disease Neuroimaging Initiative
por: Canevelli, Marco, et al.
Publicado: (2020)

Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease
por: Veitch, Dallas P., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3nf6j41e1essj8282ubdnvje21